Xavier Urbaneja, MBA, PhD

🚀 ParkourSC is Excited for LogiPharma Connect 2024! 🌍 We’re proud to join the pharma industry’s top leaders at the iconic Fairmont Le Montreux Palace in stunning Montreux, Switzerland. 🏔️ This year, the spotlight is on a vital topic for the future: Re-Establishing Foundations for Supply Chain Digital Transformation. Supply chains must evolve to stay competitive, resilient, and prepared for the future. But transformation goes beyond adopting new technologies—it requires shifting mindsets, cultivating a culture of innovation, and empowering teams to embrace change. At ParkourSC, we make Complex Decisions Simple. That’s more than a tagline—our commitment to helping you achieve real-time visibility, seamless integration, and operational excellence. 📅 Join Mark Talens and Bastian Kunze as we explore practical strategies and bold innovations to reshape the future of pharma supply chains. Let’s lead this transformation together! #LogiPharmaConnect #SupplyChainInnovation #DigitalTransformation #LifeSciences #ParkourSC

13

What challenges do you face in maintaining product integrity? Join us next week at LogiPharma 4.0 Connect in Montreux, where we will dive deep into these critical conversations with industry leaders! Discover how our end-to-end, real-time visibility solutions can address your concerns and streamline your life sciences supply chain processes. Learn how Berlinger’s and Sensitech’s technology can help address your most pressing concerns and build resilience into your operations. More information on Berlinger's SmartSystem: https://lnkd.in/eTSXXq8d Looking forward to insightful discussions with professionals! #LifeScience #SupplyChain #ColdChain #TemperatureMonitoring

29

1 Kommentar

scienceindustries most recently launched its sustainability strategy for Switzerland. A new film ‘Climate & Resources: Sustainable Innovation in Chemicals, Pharmaceuticals and Life Sciences’ now summarizes the commitment of the Swiss chemical, pharmaceutical and life sciences industries. Check out our collaboration video, which highlights our commitment to reducing our carbon footprint and contributing to Switzerland’s 2050 net-zero ambitions! #WeAreArxada #SustainableFuture #InnovativeSolutions

84

1 Kommentar

+++ 𝙱𝚒𝚘𝚌𝚒𝚍𝚊𝚕 𝚄𝚙𝚍𝚊𝚝𝚎 +++ Despite the ECHA's need to extend the deadline for its Review Programme under the Biocidal Product Regulation (#BPR), significant progress is being made by the #ECHA and its Competent Authorities in evaluating antimicrobial technologies that were available on the market prior to 2012. Up to date, almost every other antimicrobial technology for which the review has already been done, will be banned from the market: ➡ 573 out of 938 active substance-product type records have been reviewed ➡ Only 300 of them have been approved! In the case of the antimicrobial technologies based on the release of silver ions, the current situation is even more dramatic: ➡ 38 out of 72 active substance-product type records have been reviewed ➡ 𝗡𝗢𝗡𝗘 of them have been approved! ⛔ Even though available today, these technologies will be banned from the market! 👉 𝗧𝗵𝗲𝗿𝗲 𝗶𝘀 𝗮 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝗻𝗲𝘄 𝗮𝗻𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 #antimicrobial 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀!

18

Our latest #newsletter is out now! Pharma CDMOs on the Rise Key topics: The Evolution of the #CDMO Industry, Flow Chemistry, and company news about Azelis, Bilfinger, Cambrex, Covestro, Lonza, Merck KGaA, Darmstadt, Germany, Siemens, and more. Contract development and manufacturing organizations (CDMOs) have been on the rise recently. Historically, CDMOs operated on a business model which focused on serving as external service providers for manufacturing pharmaceuticals. Nowadays, CDMOs have increasingly become innovation leaders and cover more areas of the #pharma business, not just manufacturing. This change of focus has been accompanied by a change in the M&A landscape. Also, driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by CDMOs. To provide an up-to-date assessment of the sector CHEManager asked executives and industry experts from CDMOs to share their views on this changing environment and the resulting opportunities and challenges. "The most important growth drivers for CDMOs include #innovation, quality, and strategic partnerships", says Thomas P Wilson of Pfizer. Kenneth Drew of Flamma Group warns that "the competition for capacity is fierce" and suggests that "[pharma] innovators should build relationships with CDMOs that have diverse geographic footprints." Lonza's Gordon Bates explains: "Increasing complexity [...] in clinical pipelines demands both deep scientific expertise and strong process development and manufacturing innovation." Read all of the insightful views of the CDMO experts in our #CMI newsletter and in the following days on #LinkedIn: https://lnkd.in/d2yG4tW5 In the run-up to #CPHI, the world's largest event for pharma chemicals and services, we have also looked at pharma manufacturing concepts such as the adoption of Flow Chemistry, and Pharma’s Digital Transformation. Wishing you an insightful read, Ralf Kempf and Michael Reubold Editors, #CHEManager International

7

1 Kommentar

🌟🧬 VUGENE is happy to announce the launch of MODA - a Multi-Omics Data Analysis service, developed in partnership with biocrates life sciences ag. We are truly grateful to Alice Limonciel and the Biocrates team for their remarkable cooperation in this joint effort 🤝 MODA service is designed to discover relationships across multiple omics layers and helps to understand how those relationships are affected in disease. It will enable researchers to easily integrate their metabolomics and lipidomics results with the other omics in their toolbox 🛠️ MODA can enable: 🔶 Identify statistically significant changes at each omics level 🔶 Discover SNPs, methylation sites and genes that jointly affect metabolite abundance  🔶 Pin point the interactions that change in disease 🔶 Zoom into actionable targets and evaluate their potential using machine learning Multi-omics is essential for advancing our understanding of human health’s complexities, and MODA represents a significant leap forward, empowering researchers to push the boundaries of knowledge and accelerate their time to insight. Find out more about MODA here 👉 https://lnkd.in/dZbWRp4e Let’s get in touch if you are planning an experiment spanning multiple omics or already have the data. #VUGENE #collaboration #dataanalysis #multiomics #data #datascience

37

1 Kommentar

As the Biosecure Law moves closer to potential approval in the U.S., Indian CDMO players are set to seize emerging opportunities in the pharmaceutical sector. Key factors for international innovative pharmaceutical companies when selecting new partners include trust (transparency) and quality, areas where Indian CDMOs excel, especially in comparison to Chinese counterparts. While trust and quality are crucial, cost remains a significant consideration. Indian CDMOs still rely on China for many starting materials, impacting their pricing and profit margins, which could affect their competitiveness globally. I encourage leaders in the LinkedIn community to offer their perspectives on this evolving scenario. Will international companies be willing to pay a premium for Indian CDMOs in their supply chains, or will Indian players need to adapt their strategies to stay competitive? Additionally, are there other factors beyond cost that could impact the success of Indian CDMOs? Thank you for sharing your valuable insights.

50

3 Kommentare

How do we go from identifying a new virus to delivering a #vaccine - faster and smarter than ever before? Our CEO, Matthias Müllner, will tackle this crucial question alongside international experts such as Florian Krammer, Patrícia Pereira Aguilar, and Kerry Love at the European Summit of Industrial Biotechnology in Graz! Join us for the “Preparedness for Next Pandemic” session on November 14, from 10:00–12:00, chaired by Reingard Grabherr and Miriam Klausberger from #BOKU Vienna. We’re ready to accelerate pandemic preparedness! #Biotech, #Pharma, #LifeSciences, #VaccineDevelopment, #PandemicPreparedness, #ViralVectors, #Innovation

46

Navigating the complexities of formulation and with a new ingredient can be challenging, but 𝘄𝗲’𝗿𝗲 𝗵𝗲𝗿𝗲 𝘁𝗼 𝗵𝗲𝗹𝗽! Our detailed datasheet offers valuable insights into the performance of 𝐀𝐭𝐥𝐨𝐱 𝐌𝐞𝐭𝐚𝐬𝐩𝐞𝐫𝐬𝐞™ 𝟔𝟓𝟎𝐒, tested across three different WDG formulations with a variety of active ingredients.​ ​ 📊 𝐖𝐡𝐚𝐭’𝐬 𝐢𝐧𝐬𝐢𝐝𝐞?​ ✔️Physical properties and regulatory information​ ✔️Performance in WDGs and SCs formulations​ ✔️Practical guidance on how to effectively incorporate it with your existing products​ 📥 Download our datasheet now and discover how Atlox Metasperse 650S can give your formulation an upgrade: https://ow.ly/SFrX30sGzeR #Croda #CrodaCropCare #CropProtection #NewSolidDispersant #Innovation #Agrochemical #Sustainability #Formulation

4

Watch and hear from Laura how we tackle the manufacturing of nucleic acids. Reach out if you are interested! It is our pleasure to discuss your project!

10

SCHOTT Pharma with strong growth and record margin after solid year-end finish https://lnkd.in/d2Kecpsb SCHOTT Pharma SCHOTT Pharma showed a solid year-end finish and achieved all financial targets for the fiscal year 2024. Revenues in Q4 2024 amounted to EUR 237million (+4 percent year-on-year). At constant currencies, revenue grew by 9 percent year-on-year in Q4, driving revenue growth for the fiscal year 2024 to 12 percent, the top half of the previously raised guidance. EBITDA increased even stronger to EUR 66 million (+28 percent year-on-year). This was driven by the successful expansion of capacities and more than offset the continuous ramp-up efforts and underutilization. The EBITDA margin increased by more than five percentage points to 27.9 percent, both as reported and at constant currencies, which led to a higher margin of 26.9 percent for the fiscal year 2024 (FY 2023: 26.6 percent). At constant currencies, margin was even stronger at 27.8 percent. Highlights All 2024 targets met including raised revenue guidance: 12 percent revenue growth and EBITDA margin of 27.8 percent, both at constant currencies Q4 2024 revenues reached EUR 237m; EBITDA margin of 27.9 percent well above prior year FY 2024 revenues reached EUR 957m; EBITDA margin of 26.9 percent above prior year Share of strong-margin high-value solutions (HVS) at 55 percent in FY 2024 Guidance for FY 2025 reflects further strong revenue and earnings growth at constant currencies All 2024 targets achieved For FY 2024, SCHOTT Pharma achieved a strong revenue growth of 7 percent (at constant currencies: 12 percent). With that, revenue growth at constant currencies came in in the upper half of the increased FY 2024 guidance. This growth was primarily fuelled by the high demand for HVS products and SCHOTT Pharma’s continuous expansion of the corresponding capacities. 55 percent of revenue in FY 2024 came from strong-margin HVS, bringing the company closer to its mid-term target of above 60 percent. SCHOTT Pharma’s profit growth in FY 2024 outperformed the already strong revenue increase. EBITDA increased by 8 percent year-on-year to EUR 258m, resulting in a margin of 26.9 percent. At constant currencies, EBITDA growth was even higher at 17 percent year-on-year. Consequently, the EBITDA margin expanded notably to a record level of 27.8 percent. The full report is available here.

5

Memo Therapeutics or “MTx” has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. The new funding will be used to bolster the clinical advancement of MTx’s lead asset, AntiBKV for kidney transplant patients with a BK virus infection. This infection can lead to nephropathy, loss of kidney function, as well as organ failure and rejection. The disease represents a potential market in excess of $1 billion. New investors Ysios Capital and Kurma Partners participated in the extension round, joining existing Series C round investors including Pureos Bioventures, Swisscanto, Verve Ventures and Redalpine. Erik van den Berg Christoph Esslinger Lars Spenger Memo Therapeutics AG Thomas Harth Ysios Capital Hadrien Bouchez Kurma Partners Veronica Gambillara Fonck Pureos Bioventures #viralinfection #kidney #transplant #nephropathy #clinicaltrials https://lnkd.in/e7HwNkiP

7

🖐️ Five milestones for five years at our production facility in Blair, Nebraska. 🏆 The grand opening of our commercial facility marked a great leap in the Veramaris story, but our journey goes much deeper…🌊 🚀 2017-2018: dsm-firmenich and Evonik establish 50:50 joint venture and launch the Veramaris brand. 🚀 2019: The grand opening of our state-of-the-art production facility in Blair, Nebraska, substantially adding to the global supply of EPA & DHA Omega-3 fatty acids . 🚀 2021: Veramaris became the first ASC-MSC certified microalgae producer for feed. Adding substantially to the provision of certified sustainable EPA & DHA Omega-3 fatty acids. 🚀 2022: The company set its first target to reduce direct GHG emissions, approved by the Science Based Targets initiative (SBTi). Less than 18 months later, a new target was set to reduce indirect emissions too. 🚀 2023: For the first time, we were able to run our facilities at maximum capacity and prepare for a future scale-up in operations! Production volume has rocketed – achieving 50% more than in 2021. Scroll through the carousel below to see the full timeline. 👇 #AlgaeProduction #AlgalOil #FishOil #Omega3

90

In the recent edition, The Most Influential Leaders Shaping the Future of Manufacturing, 2024, CIOLOOK magazine gladly features Inga Siemsen, the Director of Manufacturing Technology & Science at Ferring Pharmaceuticals’ Kiel site, and other prominent leaders in the manufacturing sector. For More Details: https://cutt.ly/2eCHeczp #HealthcareInnovation #MedicalBreakthroughs #EmpoweringScience #TransformingHealthcare #PharmaVision #WomenInPharma #PharmaLeadership #DrivingInnovation #ciolook

124

4 Kommentare

🔬 Strategic News from faCellitate Heinz Schmid, a globally renowned expert in the life sciences industry, has joined our Advisory Board. faCellitate GmbH, a leading innovator in the field of defined surface coatings for life science consumables is thrilled to welcome Heinz Schmid, a renowned and globally recognized expert in the industry, to its advisory board. Heinz Schmid served 19 years as Managing Director of Greiner Bio-One Germany and 13 years as CEO of the Business Unit Bioscience on the managing board of Greiner Bio-One International GmbH. With his extensive experience and expertise Heinz Schmid will be invaluable in guiding the company’s strategic direction and furthering its mission to revolutionize cell culture technology and set the technological basis of future stem cell therapies. “It is a special honour to welcome Heinz Schmid to the faCellitate Advisory Board,” said Dr. Simon Widmaier, CEO of faCellitate. “his unprecedented wealth of knowledge and experience will be an integral part as we continue innovating the field of functional life science consumables. This commitment marks a significant milestone in our journey to provide researchers with the tools they need to push the boundaries of biological research globally.” “I am excited to join faCellitate’s Advisory Board and contribute to their mission of advancing life science research,” said Heinz Schmid. “faCellitate’s innovative approach and dedication to excellence align perfectly with my own values and aspirations. I look forward to working closely with the team to drive impactful advancements in the field.” faCellitate GmbH, a pioneering venture originating from BASF’s incubator Chemovator, is known for the global success of its groundbreaking BIOFLOAT™ technology for spheroid cell culture. This innovative solution is setting new standards in the field of 3D cell culture, offering unparalleled advancements for researchers, scientists and pharmaceutical development worldwide. The faCellitate technology, a unique polymeric platform, is designed to support a wide range of applications including cancer and stem cell research, drug discovery, toxicology, and tissue engineering. The technology facilitates the creation of fully synthetic, biologically relevant environments, significantly enhancing the quality and reproducibility of cell culture experiments. #faCellitate #Innovation #LifeSciences #CellCulture #BIOFLOAT

20

Register now for part 2 of our Storage and Stability webinar series: The Key to Successful Stability Storage 👉 https://lnkd.in/eGKJATSf 📅 3rd of October 2024 | 3-4pm CEST Our expert Sylvain Darondel, from Eurofins Biopharma Product Testing (France) will be sharing his knowledge on constructing the design of storage for a stability study based on the Ishikawa method: medium, material, methods, measurements, machines and manpower. During the webinar we will discuss: ◾Criteria for Storage and Flow ◾Ishikiwa diagram ◾Adaptability of Analysis #eurofins #testingforlfe #biopharma #stability #storage #webinar

5

Gain insights into the current top challenges in #CellandGeneTherapy and their solutions from Pierre Springuel at this year's #ESACT2024 . Learn more about Sartorius cell and gene therapy solutions: https://sar.to/cxfym #SimplifyingProgress #InThisTogether #AdvancedTherapies

58